Coherus Oncology, Inc.
CHRS Healthcare Biotechnology
In the quarter to June 2026, revenue grew 39.5%, EPS fell 105.1%, free cash flow fell 33.2% and total debt rose 1.03%, each against the same quarter a year earlier.
Follow CHRS
Coherus Oncology, Inc. (CHRS) EV/Sales
As of 16 October 2026, Coherus Oncology, Inc. (CHRS) trades at a EV/Sales of 5.1×. Over the past ten years it has ranged from 1.7× (June 2024) to 516× (August 2018); the current reading is higher than 52% of that period. That is below the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 4.9× | (72.66%) |
| FY2024 | 17.9× | 601.68% |
| FY2023 | 2.5× | (43.03%) |
| FY2022 | 4.5× | 10.65% |
| FY2021 | 4.0× | 73.80% |
| FY2020 | 2.3× | (34.13%) |
| FY2019 | 3.5× | (98.24%) |
| FY2017 | 201× | 3,223.89% |
| FY2016 | 6.0× | (73.84%) |
| FY2015 | 23.1× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 6.4× | 8.10% |
| Mar 2026 | 5.9× | 20.19% |
| Dec 2025 | 4.9× | (13.83%) |
| Sep 2025 | 5.7× | 204.55% |
| 37 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| CMPX Compass Therapeutics, Inc. compare | n/m |
| ADAG Adagene Inc. Sponsored ADR compare | n/m |
| IPHA Innate Pharma S.A. Sponsored ADR compare | 0.1× |
| WHWK Whitehawk Therapeutics, Inc. compare | 1.9× |
| DTIL Precision BioSciences, Inc. compare | 1.9× |
| CHRS Coherus Oncology, Inc. | 5.1× |
| MDWD MediWound Ltd. compare | 10.0× |
| ORMP Oramed Pharmaceuticals Inc. compare | 29.0× |
| VRXA Veraxa Biotech AG compare | — |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)